Barclays’s abrdn Life Sciences Investors HQL Stock Holding History

Barclays’s Portfolio HQL Stock Details HQL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-6,364	Closed	-$135K	–	4395
2021 Q3	$135K	Buy	6,364 +4,674	+277%	+$100K	﹤0.01%	3785
2021 Q2	$37K	Hold	1,690	–	–	﹤0.01%	4271
2021 Q1	$35K	Buy	+1,690	New	+$34.8K	﹤0.01%	4276

Other funds holding HQL

NIM

Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AAM

Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return

FHA

Flagship Harbor Advisors Boston, Massachusetts $2.27B AUM 18.34% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

Cohen & Steers New York $57.6B AUM 8.03% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

AUB

Atlantic Union Bankshares Glen Allen, Virginia $5.21B AUM 19.46% 1-Year Est. Return

Barclays's HQL Position: Q4 2021 in Review

Barclays sold out of abrdn Life Sciences Investors (HQL) in Q4 2021, closing a stake of 6,364 shares — an estimated $135K sold.

Barclays first reported a position in HQL in Q1 2021 and held it in 3 quarters. The position peaked at $135K in Q3 2021. 67 funds tracked by Wall St. Rank hold HQL as of Q4 2021.

Barclays reported no remaining abrdn Life Sciences Investors position as of Q4 2021 after selling out during the quarter.
Barclays sold 6,364 abrdn Life Sciences Investors shares in Q4 2021, an estimated $135K.
Barclays first reported a position in abrdn Life Sciences Investors in Q1 2021 and held it in 3 quarters.
Barclays's abrdn Life Sciences Investors position peaked at $135K in Q3 2021.
67 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q4 2021.

Based on Barclays's 13F filing for Q4 2021, filed 14 Feb 2022.